LifeScience Biologics
Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persist...
January 08, 2024 | News
First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer Collaboration includes ex...
January 05, 2024 | News
Under the terms of the collaborations, IASO Bio will receive exclusive access to the rapamycin-activated cytokine receptor (RACR™) platform, Umoja's ...
January 04, 2024 | News
BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...
January 04, 2024 | News
Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's...
January 03, 2024 | News
Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced 510(...
January 02, 2024 | News
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio") jointly announce tha...
January 01, 2024 | News
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses t...
December 29, 2023 | News
A notable highlight of the workshop was a thought-provoking panel discussion featuring serial entrepreneurs and scientific founders: Prof Chwee Teck (C.T.)...
December 29, 2023 | News
AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceuti...
December 28, 2023 | News
Orphan drugs, also known as drugs for rare diseases, are drugs for preventing, treating or diagnosing rare diseases. Being designated as orphan drugs will ...
December 28, 2023 | News
KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Di...
December 26, 2023 | News
Through the acquisition of Propella, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being develope...
December 22, 2023 | News
Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, announced its agreement with...
December 22, 2023 | News
Most Read
Bio Jobs
News
Editor Picks